Simcere Pharmaceutical Group (HKG:2096) reported a 2.6% increase in profit attributable to equity shareholders for 2024 to 733.2 million yuan, from 714.8 million yuan in the previous year, according to a filing with the Hong Kong bourse on Monday.
Earnings per share grew to 0.29 yuan from 0.27 yuan a year ago. Analysts polled by Visible Alpha estimated EPS at 0.35 yuan.
Revenue for the year increased marginally by 0.4% to 6.64 billion yuan, from 6.61 billion yuan in the prior year. Analysts polled by Visible Alpha estimated revenue at 6.71 billion yuan.
The board declared a final dividend of 0.16 yuan per share, subject to shareholders' approval. The final dividend is expected to be paid on or before July 14 to shareholders on record as of June 24.
The company's shares were down nearly 3% in recent trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.